136 related articles for article (PubMed ID: 2602637)
21. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
22. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features.
Pasqualetti P; Casale R; Collacciani A; Colantonio D
Eur J Cancer; 1991; 27(9):1123-6. PubMed ID: 1835621
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma.
Reibnegger G; Krainer M; Herold M; Ludwig H; Wachter H; Huber H
Cancer Res; 1991 Dec; 51(23 Pt 1):6250-3. PubMed ID: 1933885
[TBL] [Abstract][Full Text] [Related]
26. [Clinical features of multiple myeloma patients with extramedullary disease: a report of 40 cases from a single center].
Chen HF; Fu WJ; Wang DX; Yuan ZG; Chen YB; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):655-8. PubMed ID: 18399168
[TBL] [Abstract][Full Text] [Related]
27. [The wide variations of the clinical behavior and prognosis in multiple myeloma].
Kanoh T; Hirashimizu K
Rinsho Ketsueki; 1993 Apr; 34(4):439-43. PubMed ID: 8510330
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic significance of skeletal lesions in multiple myeloma].
Bettini R; Anzani P; Quadrelli CM; Mammano S; Rapazzini P; Marrapodi E; Sessa V
Recenti Prog Med; 1989 Jun; 80(6):300-3. PubMed ID: 2672192
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic and therapeutic significance of bone marrow biopsy in multiple myeloma. Analysis of 31 stage II A and III A patients].
Paule B; Quillard J; Medicis P; Bourgeois P; Grossin M; Bisson M; Kahn MF
Rev Rhum Mal Osteoartic; 1988 Jan; 55(1):27-32. PubMed ID: 3353673
[TBL] [Abstract][Full Text] [Related]
31. [Comparative study of 2 prognostic classification systems for myeloma and examination of the correlation between initial bone marrow plasmacytosis and prognosis. A propos of a homogeneous population of 50 patients followed from diagnosis to death].
Pesce A; Cassuto JP; Grisot C; Gratecos N; Bayle J; Viot G; Dujardin P
Nouv Rev Fr Hematol (1978); 1983; 25(5):311-7. PubMed ID: 6657481
[TBL] [Abstract][Full Text] [Related]
32. [Reproducibility of a mathematical model for calculating survival in multiple myeloma].
Pasqualetti P; Casale R; Colantonio D
Medicina (Firenze); 1989; 9(2):182-4. PubMed ID: 2811644
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
34. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).
Kudo M; Chung H; Osaki Y
J Gastroenterol; 2003; 38(3):207-15. PubMed ID: 12673442
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma in elderly patients: prognostic factors and outcome.
Anagnostopoulos A; Gika D; Symeonidis A; Zervas K; Pouli A; Repoussis P; Grigoraki V; Anagnostopoulos N; Economopoulos T; Maniatis A; Dimopoulos MA
Eur J Haematol; 2005 Nov; 75(5):370-5. PubMed ID: 16191085
[TBL] [Abstract][Full Text] [Related]
36. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation.
Gahrton G; Tura S; Ljungman P; Bladé J; Cavo M; De Laurenzi A; Façon T; Gratwohl A; Michallet M; Nikoskelainen J
Stem Cells; 1995 Aug; 13 Suppl 2():122-5. PubMed ID: 8520500
[TBL] [Abstract][Full Text] [Related]
37. [The analysis of prognostic variables in 123 patients with multiple myeloma].
Xu Y; Deng SH; Mai YJ; Li X; Qi PJ; Zhao YZ; Zou DH; Wang YF; Qian LS; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):330-4. PubMed ID: 17877163
[TBL] [Abstract][Full Text] [Related]
38. Stage and mRNA expression of survivin in lymph node as prognostic indicators in patients with oral squamous cell carcinoma.
Kim MJ; Lim KY; Kim JW; Nam IW; Lee JH; Myoung H
Cancer Lett; 2005 Jun; 224(2):253-61. PubMed ID: 15914276
[TBL] [Abstract][Full Text] [Related]
39. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
40. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]